Patients undergoing intensive chemotherapy are usually in need for central venous catheters (CVC). Due to contradictory study results, relation of insertion site and CVC-associated complication rate in these patients is not clear. We therefore retrospectively analyzed CVC-related data of all patients undergoing intensive chemotherapy with high risk of febrile neutropenia according to NCCN criteria, who received a CVC at our bone marrow transplantation unit between May 2016 and December 2019. In total, 210 patients received 281 CVC. CVC were placed via either the subclavian-vein (SCV, n = 58; 20%) or the internal-jugular-vein (IJV, n = 223; 80%). Median duration of CVC-lifetime and neutropenic days per CVC were comparable between the two groups (IJV vs SCV: 23 days vs 21 days (p = 0.16) and 12 days vs 11 days (p = 0.65)). Both, time to CVC removal due to local inflammation and time to central line-associated bloodstream infection was significantly shorter in patients with SCV catheters (p = 0.013 and p = 0.045). CVC placed in the IJV were associated with significantly less catheter-related infectious events compared with CVC placed in the SCV. This difference was consistent across different subgroups including 88 patients undergoing allogeneic stem cell transplantation.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hentrich M, Schalk E, Schmidt-Hieber M, Chaberny I, Mousset S, Buchheidt D, et al. Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. Ann Oncol. 2014. https://doi.org/10.1093/annonc/mdt545
Parienti JJ, Mongardon N, Mégarbane B, Mira JP, Kalfon P, Gros A, et al. Intravascular complications of central venous catheterization by insertion site. N Engl J Med. 2015. https://doi.org/10.1056/NEJMoa1500964
Parienti JJ, Mongardon N, Megarbane B. Intravascular complications of central venous catheterization by insertion site. J Vasc Surg. 2016. https://doi.org/10.1016/j.jvs.2016.01.007
Heidenreich D, Hansen E, Kreil S, Nolte F, Jawhar M, Hecht de Gutierrez A, et al. Influence of the insertion site on central venous catheter-related complications in patients undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2020. https://doi.org/10.1016/j.bbmt.2020.02.007
Freifeld AG, Baden LR, Brown AE, Elting LS, Gelfand M, Greene JN, et al. Fever and neutropenia clinical practice guidelines. J Natl Compr Cancer Netw. 2004. https://doi.org/10.6004/jnccn.2004.0033
Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, et al. Myeloid growth factors. J Natl Compr Cancer Netw 2013. https://doi.org/10.6004/jnccn.2013.0148
Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008. https://doi.org/10.1016/j.ajic.2008.03.002
Worth LJ, Seymour JF, Slavin MA. Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: Prospective evaluation of nontunneled devices. Support Care Cancer. 2009. https://doi.org/10.1007/s00520-008-0561-7
Dix CHK, Yeung DTO, Rule ML, Ma DDF. Essential, but at what risk? A prospective study on central venous access in patients with haematological malignancies. Intern Med J. 2012. https://doi.org/10.1111/j.1445-5994.2011.02596.x
Worth LJ, Black J, Seymour JF, Thursky KA, Slavin MA. Surveillance for catheter-associated bloodstream infection in hematology units: quantifying the characteristics of a practical case definition. Infect Control Hosp Epidemiol. 2008. https://doi.org/10.1086/528879
Dandoy CE, Ardura MI, Papanicolaou GA, Auletta JJ. Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis. Bone Marrow Transpl. 2017. https://doi.org/10.1038/bmt.2017.14
Luft D, Schmoor C, Wilson C, Widmer AF, Bertz H, Frei R, et al. Central venous catheter-associated bloodstream infection and colonisation of insertion site and catheter tip. What are the rates and risk factors in haematology patients? Ann Hematol. 2010. https://doi.org/10.1007/s00277-010-1005-2
Chaberny IF, Ruseva E, Sohr D, Buchholz S, Ganser A, Mattner F, et al. Surveillance with successful reduction of central line-associated bloodstream infections among neutropenic patients with hematologic or oncologic malignancies. Ann Hematol. 2009. https://doi.org/10.1007/s00277-008-0687-1
Poutsiaka DD, Price LL, Ucuzian A, Chan GW, Miller KB, Snydman DR. Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transpl. 2007. https://doi.org/10.1038/sj.bmt.1705690
Tanaka J, Young R, Spees L, Jenkins K, Sung AD, Martin PL, et al. Anaerobic antibiotics and the risk of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2019. https://doi.org/10.1182/blood-2019-125080
Blot F, Nitenberg GE, Chachaty E, Raynard B, Germann N, Antoun S, et al. Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet. 1999. https://doi.org/10.1016/S0140-6736(98)11134-0
Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, Grady NPO, et al. IDSA guidelines for IV catheters. Cid. 2009. https://doi.org/10.1086/599376
Lukenbill J, Rybicki L, Sekeres MA, DiGiorgio M, Fraser T, Copelan A, et al. Defining central line-associated blood stream infections following hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2012. https://doi.org/10.1182/blood.v120.21.3042.3042
DiGiorgio MJ, Fatica C, Oden M, Bolwell B, Sekeres M, Kalaycio M, et al. Development of a modified surveillance definition of central line–associated bloodstream infections for patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2012. https://doi.org/10.1086/667380
Ben-Ami R, Weinberger M, Orni-Wasserlauff R, Schwartz D, Itzhaki A, Lazarovitch T, et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol. 2008. https://doi.org/10.1128/JCM.00214-08
Mariggiò E, Iori AP, Micozzi A, Chistolini A, Latagliata R, Berneschi P, et al. Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2020. https://doi.org/10.1007/s00520-019-05269-z
O’Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control. 2011. https://doi.org/10.1016/j.ajic.2011.01.003
Heidenreich D, Muetzel E, Kreil S, Nolte F, Faust M, Jawhar M, et al. Influence of the insertion site on central venous catheter related complications in patients undergoing allogeneic hematopoietic cell transplantation, high dose therapy or induction therapy for acute leukemia. Blood. 2015. https://doi.org/10.1182/blood.v126.23.1919.1919
Goetz AM, Wagener MM, Miller JM, Muder RR. Risk of infection due to central venous catheters: effect of site of placement and catheter type. Infect Control Hosp Epidemiol. 1998. https://doi.org/10.2307/30141562
Ge X, Cavallazzi R, Li C, Pan SM, Wang Y-W, Wang F-L. Central venous access sites for the prevention of venous thrombosis, stenosis and infection. Cochrane Database Syst Rev. 2012. https://doi.org/10.1002/14651858.cd004084.pub3
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Rixecker, T., Lesan, V., Ahlgrimm, M. et al. Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy. Bone Marrow Transplant (2020). https://doi.org/10.1038/s41409-020-01003-0